<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 12 (filtered medium)">
<!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:Verdana;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:Georgia;
panose-1:2 4 5 2 5 4 5 2 3 3;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
h5
{mso-style-priority:9;
mso-style-link:"Heading 5 Char";
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:12.0pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
{mso-style-priority:99;
mso-style-link:"Balloon Text Char";
margin:0in;
margin-bottom:.0001pt;
font-size:8.0pt;
font-family:"Tahoma","sans-serif";}
span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Times New Roman","serif";
color:#000099;}
span.Heading5Char
{mso-style-name:"Heading 5 Char";
mso-style-priority:9;
mso-style-link:"Heading 5";
font-family:"Times New Roman","serif";
font-weight:bold;}
p.authors, li.authors, div.authors
{mso-style-name:authors;
margin-top:7.5pt;
margin-right:0in;
margin-bottom:0in;
margin-left:0in;
margin-bottom:.0001pt;
font-size:13.0pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
p.affiliations, li.affiliations, div.affiliations
{mso-style-name:affiliations;
margin:0in;
margin-bottom:.0001pt;
line-height:16.8pt;
font-size:10.0pt;
font-family:"Times New Roman","serif";}
span.authors4
{mso-style-name:authors4;}
span.capture-id
{mso-style-name:capture-id;}
span.z-TopofFormChar
{mso-style-name:"z-Top of Form Char";
mso-style-priority:99;
mso-style-link:"z-Top of Form";
font-family:"Arial","sans-serif";
display:none;}
span.z-BottomofFormChar
{mso-style-name:"z-Bottom of Form Char";
mso-style-priority:99;
mso-style-link:"z-Bottom of Form";
font-family:"Arial","sans-serif";
display:none;}
span.BalloonTextChar
{mso-style-name:"Balloon Text Char";
mso-style-priority:99;
mso-style-link:"Balloon Text";
font-family:"Tahoma","sans-serif";}
.MsoChpDefault
{mso-style-type:export-only;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:2080512522;
mso-list-template-ids:1662581738;}
@list l1
{mso-list-id:2102482687;
mso-list-template-ids:1933706984;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="2050" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="blue" vlink="purple">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:"Times New Roman","serif";color:#000099"><a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998">http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:"Times New Roman","serif";color:#000099"><o:p> </o:p></span></p>
<p class="MsoNormal" style="mso-line-height-alt:13.2pt"><span lang="EN" style="font-size:18.0pt;font-family:"Georgia","serif";color:#333333">Identification of Phthalates in Medications and Dietary Supplement Formulations in the United States and Canada<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:"Times New Roman","serif";color:#000099"><o:p> </o:p></span></p>
<p class="authors" style="line-height:21.6pt"><span lang="EN" style="font-size:10.0pt;font-family:"Verdana","sans-serif";color:#303030">Katherine E. Kelley<sup><a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#aff1">1</a></sup>,
Sonia Hernández-Díaz<sup><a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#aff2">2</a></sup>, Erica L. Chaplin<sup><a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#aff1">1</a></sup>, Russ Hauser<sup><a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#aff2">2</a>,<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#aff3">3</a></sup>,
Allen A. Mitchell<sup><a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#aff1">1</a></sup><o:p></o:p></span></p>
<p class="affiliations"><strong><span lang="EN" style="font-size:7.5pt;font-family:"Verdana","sans-serif";color:#303030">1</span></strong><span lang="EN" style="font-size:7.5pt;font-family:"Verdana","sans-serif";color:#303030"> Slone Epidemiology Center at
Boston University, Boston, Massachusetts, USA, <strong><span style="font-family:"Verdana","sans-serif"">2</span></strong> Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA,
<strong><span style="font-family:"Verdana","sans-serif"">3</span></strong> Occupational and Environmental Medicine and Epidemiology Program, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA<o:p></o:p></span></p>
<div style="mso-element:para-border-div;border:none;border-bottom:solid black 1.0pt;padding:0in 0in 2.0pt 0in">
<p class="MsoNormal" style="margin-top:15.0pt;line-height:21.6pt;border:none;padding:0in">
<a name="abstract0" id="abstract0"></a><span lang="EN" style="font-size:14.5pt;font-family:"Georgia","serif";color:#333333">Abstract <a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#top"><span style="font-size:8.5pt;font-family:"Verdana","sans-serif";color:black;text-decoration:none">Top</span></a><o:p></o:p></span></p>
</div>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Background: In animal studies, some
<i>ortho</i>-phthalates, including di(2-ethylhexyl) phthalate (DEHP) and di-<i>n</i>-butyl phthalate (DBP), have been shown to be reproductive and developmental toxicants. Human studies show widespread population exposure to background levels of phthalates.
Limited evidence suggests that particularly high exposure levels may result from orally ingested medicinal products containing phthalates as excipients (inactive ingredients).<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Objective: In this study we aimed to identify and describe the scope of prescription (RX) and nonprescription (over-the-counter; OTC) medicinal
products and dietary supplements marketed in the United States and Canada since 1995 that include phthalates as excipients.<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Methods: We used lists of modified-release drug products to identify potential drug products. Inclusion of phthalates was verified using available
electronic databases, print references, published package inserts, product packages, and direct communication from manufacturers. Additional products were identified using Internet searches utilizing keywords for phthalates.<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Results: Based on labeling information, 6 RX drug products included DBP as an excipient, and 45 specified the use of diethyl phthalate (DEP).
Phthalate polymers with no known toxicity—hypromellose phthalate (HMP), cellulose acetate phthalate (CAP), and polyvinyl acetate phthalate (PVAP)—were included in 75 RX products. Three OTC drug and dietary supplement products listed DBP, 64 listed DEP, and
> 90 indicated inclusion of polymers.<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Conclusions: Numerous RX and OTC drug products and supplements from a wide range of therapeutic categories may use DBP or DEP as excipients
in oral dosage forms. The potential effects of human exposure to these phthalates through medications are unknown and warrant further investigation.<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom:12.0pt;line-height:21.6pt"><strong><span lang="EN" style="font-family:"Verdana","sans-serif";color:#303030">*********<o:p></o:p></span></strong></p>
<p class="MsoNormal" style="margin-bottom:12.0pt;line-height:21.6pt"><strong><span lang="EN" style="font-family:"Verdana","sans-serif";color:#303030">Keywords:
</span></strong><span class="capture-id"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">coating</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">,
<span class="capture-id">dietary supplements</span>, <span class="capture-id">excipients</span>,
<span class="capture-id">medications</span>, <span class="capture-id">phthalates</span>.<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom:12.0pt;line-height:21.6pt"><strong><span lang="EN" style="font-family:"Verdana","sans-serif";color:#303030">Citation:
</span></strong><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Kelley KE, Hernández-Díaz S, Chaplin EL, Hauser R, Mitchell AA 2012. Identification of Phthalates in Medications and Dietary Supplement Formulations in
the United States and Canada. Environ Health Perspect 120:379-384. http://dx.doi.org/10.1289/ehp.1103998<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom:12.0pt;line-height:21.6pt"><strong><span lang="EN" style="font-family:"Verdana","sans-serif";color:#303030">Received:</span></strong><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">
26 May 2011; </span><strong><span lang="EN" style="font-family:"Verdana","sans-serif";color:#303030">Accepted:</span></strong><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"> 08 December 2011;
</span><strong><span lang="EN" style="font-family:"Verdana","sans-serif";color:#303030">Online:</span></strong><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"> 15 December 2011<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom:12.0pt;line-height:21.6pt"><a name="cor1"></a><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Address correspondence to K.E. Kelley, Slone Epidemiology Center, 1010 Commonwealth
Ave., Boston, MA 02215 USA. Telephone: (617) 734-6006. Fax: (617) 738-5119. E-mail:
<a href="mailto:kekelley@bu.edu">kekelley@bu.edu</a><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom:12.0pt;line-height:21.6pt"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">This work was supported by grant R01 HD059861 from the
<i>Eunice Kennedy Shriver</i> National Institute of Child Health and Human Development, National Institutes of Health, and ES000002 from the National Institute of Environmental Health Sciences, National Institutes of Health.<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom:12.0pt;line-height:21.6pt"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">K.E.K and A.A.M. are employed by and E.L.C. was previously associated with the Slone Epidemiology Center,
which receives funding for unrelated research from various pharmaceutical companies. S.H.D. and A.A.M. have received unrestricted research and training grants from pharmaceutical companies, some of which manufacture drugs discussed in this article. The remaining
author declares he has no actual or potential competing financial interests.<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom:12.0pt;line-height:21.6pt"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">***************<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Some
<i>ortho</i>-phthalates, including di(2-ethylhexyl) phthalate (DEHP) and di-<i>n</i>-butyl phthalate (DBP), have been identified as reproductive and developmental toxicants in laboratory animals (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r16">Foster
2005</a>; <a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r21">
Howdeshell et al. 2008</a>). Similar effects have not been reported in animals exposed to diethyl phthalate (DEP); however, limited human studies have suggested a possible association between DEP exposure and male reproductive health outcomes (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r36">Swan
2008</a>). Studies have shown widespread population exposure to background levels of phthalates (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r33">Silva et al. 2004</a>). Of concern, particularly high exposure levels may result
from orally ingested medicinal products containing phthalates as inactive ingredients. For example, increased urinary concentrations of phthalate metabolites were first reported for an individual taking a mesalamine product (Asacol; Warner Chilcott Pharmaceuticals
Inc., Mason, OH) (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r17">Hauser et al. 2004</a>) and later confirmed for individuals taking mesalamine and other drug products (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r20">Hernández-Díaz
et al. 2009</a>). High urinary concentrations of phthalate metabolites have also been identified in patients with cystic fibrosis who used pancreatic enzyme products (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r22">Keller
et al. 2009</a>). This has led to increased interest in identifying additional drug products that contain phthalates as inactive ingredients.<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Inactive ingredients (excipients) are defined as “any component other than the active ingredient in a drug product” (FDA 2011). These various
compounds may be used in drug formulations for a number of functions related to the preparation and stability of the physical dosage form or the delivery of active ingredients (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r31">Rowe
et al. 2009</a>). Excipients used in specialized drug product formulations may permit
<i>a</i>) localized availability of active medications in various sections of the gastrointestinal (GI) tract,
<i>b</i>) controlled release of a medication over time, or <i>c</i>) through the skin. Phthalates, in combination with various polymers, may be used as plasticizers and film coating agents in orally ingested solid pharmaceutical dosage forms and in numerous
types of modified-release drug delivery systems such as enteric-coated and delayed-release tablets, pelletized delayed-release capsules, enteric-coated capsules, and controlled-release transdermal films (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r2">Allen
et al. 2005</a>).<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Several different phthalates are currently used as excipients in approved pharmaceutical formulations: diethyl phthalate (DEP), dibutyl phthalate
(DBP), dimethyl phthalate (DMP), dioctylphthalate (DOP), hypromellose phthalate (HMP), cellulose acetate phthalate (CAP), polyvinyl acetate phthalate (PVAP), and polyethylene terphthalate (PET) [Food and Drug Administration (FDA) 2010b]. These compounds are
not themselves technically “approved” for general use as excipients; rather, they are permitted to be included in their corresponding approved drug products, with maximum levels designated for each type of dosage form and route of administration (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r29">Osterberg
and See 2003</a>; <a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r35">
Steinberg and Silverstein 2003</a>). The maximum amount of DBP used in specific FDA-approved drug products ranges from 1.70 mg for a delayed-action, enteric-coated tablet formulation to 11.18 mg for an extended-release capsule product. DEP has been approved
at amounts ranging from 0.5 mg for an uncoated, chewable tablet to 16.8 mg for a delayed-action, enteric-coated capsule (FDA 2010b).<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Nonprescription pharmaceutical (over-the-counter; OTC) and dietary supplement products may contain excipients found in approved prescription
(RX) products; however, their composition is not always reviewed prior to marketing. OTC drug products marketed under monograph guidelines do not require premarket review of their ingredients, but contents are reviewed for products approved under new drug
applications (NDAs) and abbreviated NDAs (ANDAs) (FDA 2010a). Dietary supplements are regulated as food products under the Dietary Supplement Health and Education Act of 1994 (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r10">DSHEA
1994</a>), and their formulations do not require approval prior to marketing unless they contain a new dietary ingredient (FDA 2009).<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Manufacturers are required to disclose a listing of inactive ingredients in drug product labeling, except when they are used in patented delivery
mechanisms where the composition is considered to be a confidential trade secret (U.S. Pharmacopeial Convention 2009). Although the FDA might have information on the type and amount of phthalates used in specific approved drug products, they cannot make the
information public because of its proprietary nature.<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">In this study we sought to identify and describe the scope of medicinal pharmaceutical products and dietary supplements marketed in the United
States and Canada since 1995 that could be confirmed to contain phthalates as excipients based on available product information supplied by regulators, manufacturers, labelers, distributors, and marketers of these products.<o:p></o:p></span></p>
<div style="mso-element:para-border-div;border:none;border-bottom:solid black 1.0pt;padding:0in 0in 2.0pt 0in">
<p class="MsoNormal" style="margin-top:15.0pt;line-height:21.6pt;border:none;padding:0in">
<span lang="EN" style="font-size:14.5pt;font-family:"Georgia","serif";color:#333333">Methods <a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#top"><span style="font-size:8.5pt;font-family:"Verdana","sans-serif";color:black;text-decoration:none">Top</span></a><o:p></o:p></span></p>
</div>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">A search of the published literature on the use of phthalates in orally ingested medications suggested that phthalates are frequently included
as inactive ingredients in modified-release drug formulations (i.e., controlled-release, delayed-release, or targeted-release systems), as well as in formulations for film coatings. Drug products using these formulations rely on the integrity of their coating
systems for proper delivery of their active ingredients and therefore should not be crushed or chewed. Lists of drug products that are not recommended to be crushed or chewed have been published for reference by health care professionals to ensure their proper
administration (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r23">Mitchell 2011</a>; Thomson PDR 2006). We used these lists, which included approximately 450 product names, to complete an initial screen of drug product labeling
for the inclusion of phthalates as excipients.<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">All inactive ingredients for RX medications on the “do not crush list” were first reviewed using a combination of print and electronic resources
including the <i>Physicians’ Desk Reference</i> (Thomson Healthcare 1995–2010a), FDA Approved Drug Products database (Drugs@FDA; FDA 2011b), DailyMed [National Library of Medicine (NLM) 2011a], and LabelDataPlus (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r30">Reed
Technology and Information Services Inc. 2011</a>). Canadian products with comparable active ingredients and formulations were researched by using any available monographs from the Health Canada Drug Product Database (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r18">Health
Canada 2011a</a>) and the <i>CPS: Compendium of Pharmaceuticals and Specialties</i> (Canadian Pharmaceutical Association 1995–2006). Names of brand and generic drug products marketed since 1995 appearing on the lists were searched within each available electronic
or print reference, and all potential modified-release formulations were selected from the results. Once a label was located, we searched the document for all inactive ingredients. If multiple labels were available within a database, we investigated all potential
inactive ingredient formulation changes by reviewing the older labels. If an older formulation of the product contained phthalates but the newer formulations did not, we searched all available labels by revision date to determine when the formulation changed.
If none of the available compendia provided sufficient label information for a product, we searched the manufacturer or distributor website. If no label was found, we contacted the manufacturer and requested a copy of the package insert.<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">We performed further Internet searches using terms containing “phthalate” and “medication,” or suspected medication names and drug classes
(e.g., bisacodyl, enzyme), to locate additional products and product categories. Patents for proprietary drug delivery systems were reviewed for the use of phthalate plasticizers in specific drug products or groups of products.<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Several OTC medications and dietary supplement products were listed on the “do not crush” list; however, most available references including
the <i>Physicians’ Desk Reference for Nonprescription Drugs, Dietary Supplements, and Herbs</i> (Thomson Healthcare 1995–2010b), Drugs@FDA, LabelDataPlus, DailyMed, and Dietary Supplements Labels Database (NLM 2011b) either did not include these products or
did not provide complete, searchable label information on their inactive ingredients. For these products, we obtained detailed information on inactive ingredients from manufacturer and distributor web sites, or if possible, directly from product package labeling
retrieved from store shelves. Canadian dietary supplement products were searched using the Health Canada Licensed Natural Health Products Database (LNHPD;
<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r19">
Health Canada 2011b</a>), which currently contains information on approximately 16,000 licensed dietary supplements available in solid oral dosage forms.<o:p></o:p></span></p>
<div style="mso-element:para-border-div;border:none;border-bottom:solid black 1.0pt;padding:0in 0in 2.0pt 0in">
<p class="MsoNormal" style="margin-top:15.0pt;line-height:21.6pt;border:none;padding:0in">
<span lang="EN" style="font-size:14.5pt;font-family:"Georgia","serif";color:#333333">Results <a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#top"><span style="font-size:8.5pt;font-family:"Verdana","sans-serif";color:black;text-decoration:none">Top</span></a><o:p></o:p></span></p>
</div>
<p style="line-height:21.6pt"><i><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Use in prescription drugs.</span></i><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030"> Various
phthalates were identified in RX medications available in the United States and Canada across a wide variety of therapeutic classes, including analgesic, antibiotic, GI, cardiovascular, and antiepileptic drug products. As expected, we found that phthalates
were most commonly used in modified-release RX drug formulations that provided timed-release and targeted-release of active ingredients. Of the RX products that were identified, 75 contained the phthalate polymers HMP, CAP, and PVAP (data not shown), and 50
contained the <i>ortho</i>-phthalates DEP and/or DBP (6 contained DBP, and 1 contained both DEP and DBP) (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#t1">Table 1</a>).<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height:21.6pt;background:#D2F7FF"><a name="t1" id="t1"></a><a href="http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t001" title="Click for larger image "></a><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
<v:stroke joinstyle="miter" />
<v:formulas>
<v:f eqn="if lineDrawn pixelLineWidth 0" />
<v:f eqn="sum @0 1 0" />
<v:f eqn="sum 0 0 @1" />
<v:f eqn="prod @2 1 2" />
<v:f eqn="prod @3 21600 pixelWidth" />
<v:f eqn="prod @3 21600 pixelHeight" />
<v:f eqn="sum @0 0 1" />
<v:f eqn="prod @6 1 2" />
<v:f eqn="prod @7 21600 pixelWidth" />
<v:f eqn="sum @8 21600 0" />
<v:f eqn="prod @7 21600 pixelHeight" />
<v:f eqn="sum @10 21600 0" />
</v:formulas>
<v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect" />
<o:lock v:ext="edit" aspectratio="t" />
</v:shapetype><v:shape id="Picture_x0020_2" o:spid="_x0000_s1031" type="#_x0000_t75" alt="thumbnail" href="http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t001" title=""Click for larger image "" style='position:absolute;margin-left:0;margin-top:0;width:52.5pt;height:66.75pt;z-index:3;visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;mso-position-horizontal:left;mso-position-horizontal-relative:text;mso-position-vertical:absolute;mso-position-vertical-relative:line' o:allowoverlap="f" o:button="t">
<v:imagedata src="cid:image001.png@01CD7A0B.1BECDFF0" o:title="thumbnail" />
<w:wrap type="square" anchory="line"/>
</v:shape><![endif]--><![if !vml]><a href="http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t001"><img border="0" width="70" height="89" src="cid:image001.png@01CD7A0B.1BECDFF0" align="left" alt="thumbnail" title=""Click for larger image "" v:shapes="Picture_x0020_2"></a><![endif]><a href="http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t001" title="Click for larger image "></a><span lang="EN" style="font-size:7.5pt;font-family:"Verdana","sans-serif";color:#303030"><o:p></o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:3.75pt;margin-right:0in;margin-bottom:3.75pt;margin-left:0in;line-height:21.6pt;background:#D2F7FF">
<strong><span lang="EN" style="font-size:7.5pt;font-family:"Verdana","sans-serif";color:#303030"><a href="http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t001">Table 1.
</a> (<a href="http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t001"><span style="font-weight:normal">http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t001</span></a></span></strong><strong><span lang="EN" style="font-size:7.5pt;font-family:"Verdana","sans-serif";color:#000099">)</span></strong><strong><span lang="EN" style="font-size:7.5pt;font-family:"Verdana","sans-serif";color:#303030"><o:p></o:p></span></strong></p>
<p class="MsoNormal" style="mso-margin-top-alt:3.75pt;margin-right:0in;margin-bottom:3.75pt;margin-left:0in;line-height:21.6pt;background:#D2F7FF">
<span lang="EN" style="font-size:7.5pt;font-family:"Verdana","sans-serif";color:#303030"><o:p> </o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:3.75pt;margin-right:0in;margin-bottom:3.75pt;margin-left:0in;line-height:21.6pt;background:#D2F7FF">
<span lang="EN" style="font-size:7.5pt;font-family:"Verdana","sans-serif";color:#303030">Prescription drug products marketed in the United States and Canada listing
<i>ortho</i>-phthalates as inactive ingredients in product labeling, 1995–2011.<o:p></o:p></span></p>
<p style="line-height:21.6pt"><i><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Use in OTC drugs and dietary supplements.</span></i><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">
Enteric coatings, film coatings, and specialized capsule formulations utilizing phthalates were noted for a number of different product categories and purposes in OTC drugs and supplements. These functions included prevention of premature degradation of substances
such as enzymes, acid reducers, and probiotics by stomach acid; reduce stomach upset from iron and laxatives; minimize the aftertaste from fish oil and garlic; and produce soft gelatin capsules (i.e., “softgels”) that may be easier to swallow or contain solubilized
drugs and oils (e.g., ibuprofen, fish oil).<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Thirty-eight of the OTC drug products (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#t2">Table 2</a>) and
24 of the dietary supplement products (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#t3">Table 3</a>) located listed DEP, and 93 included phthalate polymers (data not shown). Although there were only 3 ANDAs for OTC ranitidine
detailing the use of DEP, they were linked to label information for an additional 31 private label antacid products. Only 1 OTC drug available both in the United States and Canada [Dulcolax Laxative Tablets (Boehringer Ingelheim Pharmaceuticals, Ridgefield,
CT, USA; and Boehringer Ingelheim (Canada) Ltd./Ltée, Burlington, Ontario, Canada] and 2 older formulations of dietary supplement products listed DBP [Venastat Leg Vein Health (Boehringer Ingelheim Pharmaceuticals) and Wobenzym N (Mucos Pharma, Průhonice,
Czech Republic)].<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height:21.6pt;background:#D2F7FF"><a name="t2" id="t2"></a><a href="http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t002" title="Click for larger image "></a><!--[if gte vml 1]><v:shape id="Picture_x0020_3" o:spid="_x0000_s1030" type="#_x0000_t75" alt="thumbnail" href="http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t002" title=""Click for larger image "" style='position:absolute;margin-left:0;margin-top:0;width:52.5pt;height:42.75pt;z-index:2;visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;mso-position-horizontal:left;mso-position-horizontal-relative:text;mso-position-vertical:absolute;mso-position-vertical-relative:line' o:allowoverlap="f" o:button="t">
<v:imagedata src="cid:image002.png@01CD7A0B.1BECDFF0" o:title="thumbnail" />
<w:wrap type="square" anchory="line"/>
</v:shape><![endif]--><![if !vml]><a href="http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t002"><img border="0" width="70" height="57" src="cid:image002.png@01CD7A0B.1BECDFF0" align="left" alt="thumbnail" title=""Click for larger image "" v:shapes="Picture_x0020_3"></a><![endif]><a href="http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t002" title="Click for larger image "></a><span lang="EN" style="font-size:7.5pt;font-family:"Verdana","sans-serif";color:#303030"><o:p></o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:3.75pt;margin-right:0in;margin-bottom:3.75pt;margin-left:0in;line-height:21.6pt;background:#D2F7FF">
<strong><span lang="EN" style="font-size:7.5pt;font-family:"Verdana","sans-serif";color:#303030"><a href="http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t002">Table 2.
</a> (<a href="http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t002"><span style="font-weight:normal">http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t002</span></a></span></strong><strong><span lang="EN" style="font-size:7.5pt;font-family:"Verdana","sans-serif";color:#000099">)</span></strong><strong><span lang="EN" style="font-size:7.5pt;font-family:"Verdana","sans-serif";color:#303030"><o:p></o:p></span></strong></p>
<p class="MsoNormal" style="mso-margin-top-alt:3.75pt;margin-right:0in;margin-bottom:3.75pt;margin-left:0in;line-height:21.6pt;background:#D2F7FF">
<span lang="EN" style="font-size:7.5pt;font-family:"Verdana","sans-serif";color:#303030"><o:p> </o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:3.75pt;margin-right:0in;margin-bottom:3.75pt;margin-left:0in;line-height:21.6pt;background:#D2F7FF">
<span lang="EN" style="font-size:7.5pt;font-family:"Verdana","sans-serif";color:#303030">Nonprescription drugs products marketed in the United States and Canada listing
<i>ortho</i>-phthalates as inactive ingredients in product labeling, 1995–2011.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height:21.6pt;background:#D2F7FF"><a name="t3" id="t3"></a><a href="http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t003" title="Click for larger image "></a><!--[if gte vml 1]><v:shape id="Picture_x0020_4" o:spid="_x0000_s1029" type="#_x0000_t75" alt="thumbnail" href="http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t003" title=""Click for larger image "" style='position:absolute;margin-left:0;margin-top:0;width:52.5pt;height:27.75pt;z-index:1;visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;mso-position-horizontal:left;mso-position-horizontal-relative:text;mso-position-vertical:absolute;mso-position-vertical-relative:line' o:allowoverlap="f" o:button="t">
<v:imagedata src="cid:image003.png@01CD7A0B.1BECDFF0" o:title="thumbnail" />
<w:wrap type="square" anchory="line"/>
</v:shape><![endif]--><![if !vml]><a href="http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t003"><img border="0" width="70" height="37" src="cid:image003.png@01CD7A0B.1BECDFF0" align="left" alt="thumbnail" title=""Click for larger image "" v:shapes="Picture_x0020_4"></a><![endif]><a href="http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t003" title="Click for larger image "></a><span lang="EN" style="font-size:7.5pt;font-family:"Verdana","sans-serif";color:#303030"><o:p></o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:3.75pt;margin-right:0in;margin-bottom:3.75pt;margin-left:0in;line-height:21.6pt;background:#D2F7FF">
<strong><span lang="EN" style="font-size:7.5pt;font-family:"Verdana","sans-serif";color:#303030"><a href="http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t003">Table 3.
</a> (<a href="http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t003"><span style="font-weight:normal">http://ehp03.niehs.nih.gov/article/slideshow.action?uri=info:doi/10.1289/ehp.1103998&imageURI=info:doi/10.1289/ehp.1103998.t003</span></a>)</span></strong><span lang="EN" style="font-size:7.5pt;font-family:"Verdana","sans-serif";color:#303030"><o:p></o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:3.75pt;margin-right:0in;margin-bottom:3.75pt;margin-left:0in;line-height:21.6pt;background:#D2F7FF">
<span lang="EN" style="font-size:7.5pt;font-family:"Verdana","sans-serif";color:#303030">Dietary supplements marketed in the United States and Canada listing
<i>ortho</i>-phthalates as inactive ingredients in product labeling, 1995–2011.<o:p></o:p></span></p>
<p style="line-height:21.6pt"><i><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Canada.</span></i><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030"> Several RX and OTC medications
approved for use in both the United States and Canada contained the same inactive ingredients in the product labeling (e.g., Asacol, Dulcolax) (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#t1">Tables 1</a> and
<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#t2">
2</a>); however there were some differences. Of particular note, the U.S. product labeling for Vivotif (Typhoid Vaccine Live Oral Ty21a) (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r5">Berna Biotech Ltd. 2006</a>) did not
detail the use of any phthalates, whereas the monograph for the Canadian product (Crucell Switzerland LTD 2010) specified use of “3–8 mg” of DBP and DEP and “27–33 mg” of HMP in the lacquer coating of each capsule. Several U.S. products were not available
in Canada (e.g., Cardizem CD 360 mg, Dilt-CD), and some Canadian products were not distributed in the United States (e.g., Rhotral, Parsitan). In the LNHPD (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r19">Health Canada 2011b</a>),
49 licensed supplement products were linked to phthalates as nonmedicinal ingredients, including 14 noted as containing DEP (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#t3">Table 3</a>).<o:p></o:p></span></p>
<p style="line-height:21.6pt"><i><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Changes over time.</span></i><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030"> A handful of products
changed the use of specific excipients over time either by removing specific phthalates or adding phthalates to newly approved formulations. Solvay Pharmaceuticals removed DBP from its new FDA-approved formulations of pancrelipase capsules in April 2009. The
older formulation, Creon Minimicrospheres, (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r34">Solvay Pharmaceuticals Inc. 2006</a>), which contained DBP and HMP, was replaced with Creon Delayed Release Capsules (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r1">Abbott
Laboratories 2011</a>). New formulations for two strengths of OTC and RX ranitidine tablets from one manufacturer (Wockhardt USA LLC, Parsippany, NJ) that were approved in 2007, 2008, and 2009 (Wockhardt USA LLC 2007, 2008, 2009) used DEP as a film coating
agent, whereas labels for > 30 earlier approved ranitidine products did not list any phthalates.<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">In May 2010, Warner Chilcott modified the labeling for Asacol and Asacol HD under the sections “Precautions” and “Use in Specific Populations.”
The new labels provided cautions on use during pregnancy based on animal studies of DBP exposure and also added the estimated human daily intake of DBP from the maximum recommended daily dose of each product, “about 21 mg” and “about 48 mg” for Asacol and
Asacol HD, respectively (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r41">Warner Chilcott Pharmaceuticals Inc. 2010a</a>,
<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r42">
2010b</a>)<o:p></o:p></span></p>
<p style="line-height:21.6pt"><i><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Use in specific formulations.</span></i><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030"> Inclusion
of phthalates—as well as the specific type of phthalate—in formulations for a particular drug was manufacturer specific, and on occasion dosage-form and strength specific. For example, the calcium channel blockers verapamil and diltiazem were available from
18 manufacturers in a number of strengths and time-release tablet and capsule formulations that contained different excipients. Although we found that DEP was included in two verapamil extended-release capsule products, both from one manufacturer (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r25">Mylan
Pharmaceuticals Inc. 2010a</a>, <a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r26">
2010b</a>), other tablet and capsule formulations did not contain DEP. Among diltiazem products, only one of five strengths of Cardizem CD capsules (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r6">BTA Pharmaceuticals Inc.
2010</a>) listed DEP, whereas manufacturers of other specific diltiazem capsule products utilized phthalates across all strengths: DBP in Dilt-CD (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r3">Apotex Inc. 2011</a>), DEP
in Diltiazem Extended-Release, Twice-A-Day (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r24">Mylan Pharmaceuticals Inc. 2006</a>), and HMP in Diltia XT (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r43">Watson
Pharma Inc. 2008</a>).<o:p></o:p></span></p>
<p style="line-height:21.6pt"><i><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Other sources of information.</span></i><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030"> Detailed
Internet searches led to the identification of two phthalate-containing products in patented release mechanisms, despite the fact that phthalates were not listed in the corresponding product labels. In a lawsuit brought against several manufacturers attempting
to introduce new generic omeprazole products into the market in 2001, the manufacturer of Prilosec Delayed Release Capsules (AstraZeneca Pharmaceuticals LP, Wilmington, DE) argued that the new formulations infringed on certain sections of their patent involving
the use of phthalates, including DEP and HMP, as coating agents (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r4">Astra Aktiebolag et al.
<i>v</i>. Andrx Pharmaceuticals Inc., et al., 2002</a>). Communication with the manufacturer (AstraZeneca, personal communication) confirmed the use of HMP in the enteric coating layer of the pelletized drug found within the capsules. A similar patent infringement
case (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r32">Shire LLC
<i>v</i>. Nostrum Pharmaceuticals Inc. 2008</a>) detailed the use of HMP in patents for carbamazepine extended release capsules (Carbatrol; Shire US Inc., Wayne, PA).<o:p></o:p></span></p>
<div style="mso-element:para-border-div;border:none;border-bottom:solid black 1.0pt;padding:0in 0in 2.0pt 0in">
<p class="MsoNormal" style="margin-top:15.0pt;line-height:21.6pt;border:none;padding:0in">
<span lang="EN" style="font-size:14.5pt;font-family:"Georgia","serif";color:#333333">Discussion <a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#top"><span style="font-size:8.5pt;font-family:"Verdana","sans-serif";color:black;text-decoration:none">Top</span></a><o:p></o:p></span></p>
</div>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">In this study, we identified a number of different phthalates as excipients in a variety of pharmaceutical products and dietary supplements
sold in the United States and Canada. Although most of these products included phthalate polymers that are considered to be of low or no known toxicity, label information for several product formulations contained the phthalate diester DBP, which has been
shown to cause adverse effects in experimental animal studies.<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Although we attempted to review as many product listings as possible, this list cannot be considered comprehensive. Information on a number
of products was unavailable due to product discontinuation and changes in manufacturers. Products may have changed their formulation over time, and the information available at the time of this review may not reflect the most recent version of the product
formulation. In addition, some product information was incomplete (all inactive ingredients were not listed), which required that we seek information directly from the manufacturer. Although the FDA might have a more complete listing of products, including
the type and amount of phthalate in specific drug products, this information is considered proprietary and cannot be accessed. Given the thousands of orally ingested products on the market (RX, OTC, and dietary supplements), it is difficult to quantify the
prevalence of phthalate-containing products. However, it is informative to identify specific drug products that have included phthalates in their formulations.<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">It is also important to note the limitations and difficulties that were associated with some of the references used to compile the information
for this study. Information on the specific excipients used in these products was generally available; however, it was not centrally located, comprehensive, or easily queried.<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">The FDA Approved Drug Products Database (Drugs@FDA) did not contain labels for all products, especially generics, and only some entries contained
copies of approval history documents that detail product formulations. Several additional labels were available on LabelDataPlus, DailyMed, or manufacturer web sites, demonstrating that electronic versions of the labels were available but were not linked to
the FDA database. For example, detailed label information for prescription and OTC ranitidine tablets from Wockhardt was available on DailyMed and LabelDataPlus but not on Drugs@FDA. The available OTC labels linked these approved products to labeling for several
private label distributors (e.g., mass merchandise, grocery and drug store chains); however, these labelers and distributors often change the source for their private-label products over time. Neither Drugs@FDA nor Health Canada’s Drug Product Database permitted
a systematic search of excipients in RX and OTC drug products. LabelDataPlus permitted queries for inactive ingredients; however, it was not comprehensive.<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">The
<i>Physicians’ Desk Reference</i> (Thomson Healthcare 1995–2010a) contained some additional product labels, especially older versions of labels and discontinued products (e.g., Theo-Dur; Key Pharmaceuticals Inc., Kenilworth, NJ); however, available information
was limited to manufacturers who elected to include their products in the reference.<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">We found several NDAs and ANDAs containing information on excipients using Drugs@FDA. However, because of the proprietary nature of the formulations,
in most instances information concerning the type and amount of inactive ingredients used were redacted from the available documents. In LabelDataPlus, the strength of each inactive ingredient was provided for one omeprazole product—Omesec Delayed Release
Capsules—listed as containing 0.144 mg DEP (Corporacion <a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r8">
Informasa 2010</a>); however, this was the only drug product for which we found this level of information to be available.<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">For a number of dietary supplement products, the available information on inactive ingredients was incomplete or unclear. Available label
information sometimes described products as having an “enteric coating” without a specific listing of the components, making it impossible to determine whether any phthalates were present. Some fish oil capsules labels stated that they “may also contain” a
variety of excipients, including HMP. Canada’s LNHPD (<a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#r19">Health Canada 2011b</a>) and the NLM Dietary Supplements Labels Database permitted searches by inactive ingredients for
licensed health products and supplements, but these databases are not comprehensive directories of marketed products.<o:p></o:p></span></p>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">In order to create a comprehensive listing of phthalate-containing products, individual manufacturers would have to provide information on
their use of phthalates in specific product formulations. Such a list (similar to those available for other excipients such as gelatin or gluten) would not only facilitate critical research on the risks and safety of phthalate-containing medications but also
would allow prescribers and consumers to select alternative products that are phthalate free. Estimates of exposure from these products can vary according to manufacturer-specific formulation characteristics, including the dosage form, dose, date of use, and
country of manufacture. Researchers, consumers, and health care providers may need to contact manufacturers directly to confirm the presence of phthalates and the amounts used in a particular drug product.<o:p></o:p></span></p>
<div style="mso-element:para-border-div;border:none;border-bottom:solid black 1.0pt;padding:0in 0in 2.0pt 0in">
<p class="MsoNormal" style="margin-top:15.0pt;line-height:21.6pt;border:none;padding:0in">
<a name="" id="Conclusion"></a><span lang="EN" style="font-size:14.5pt;font-family:"Georgia","serif";color:#333333">Conclusion <a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#top"><span style="font-size:8.5pt;font-family:"Verdana","sans-serif";color:black;text-decoration:none">Top</span></a><o:p></o:p></span></p>
</div>
<p style="line-height:21.6pt"><span lang="EN" style="font-size:9.0pt;font-family:"Verdana","sans-serif";color:#303030">Using a combination of resources, we were able to identify > 100 drug and dietary supplement products that indicated the use of
<i>ortho-</i>phthalates as excipients, including labels of 50 RX, 40 OTC, and 26 dietary supplement product formulations that listed DEP and/or DBP (9 contained DBP, and 1 contained both DEP and DBP). The potential effects of human exposure to these phthalates
through medications are unknown and warrant further investigation. The present findings should assist researchers in conducting the necessary studies of risk and safety of phthalates in human populations, but such efforts are limited by the lack of centralized,
comprehensive, and publically available information on the presence of phthalates in the full range of RX, OTC, and dietary supplement products. Future research should pay particular attention to the amount of phthalate, specifically DBP, used in each dosage
form so that estimates of exposure from medications and supplements can be quantified.<o:p></o:p></span></p>
<div style="mso-element:para-border-div;border:none;border-bottom:solid black 1.0pt;padding:0in 0in 2.0pt 0in">
<p class="MsoNormal" style="margin-top:15.0pt;line-height:21.6pt;border:none;padding:0in">
<a name="references" id="references"></a><span lang="EN" style="font-size:14.5pt;font-family:"Georgia","serif";color:#333333">References <a href="http://ehp03.niehs.nih.gov/article/info%3Adoi%2F10.1289%2Fehp.1103998#top"><span style="font-size:8.5pt;font-family:"Verdana","sans-serif";color:black;text-decoration:none">Top</span></a><o:p></o:p></span></p>
</div>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r1" id="r1"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">1.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Abbott Laboratories 2011. Creon Delayed-Release Capsules. North Chicago, IL:Abbott Laboratories. Available:
<a href="http://www.rxabbott.com/pdf/creon_PI.pdf">http://www.rxabbott.com/pdf/creon_PI.pdf</a> [accessed 23 January 2012]
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r2" id="r2"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">2.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Allen LV, Popovich NG, Ansel HC, eds</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">
2005. Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems. 8th ed. Baltimore, MD: Lippincott Williams & Wilkins.
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r3" id="r3"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">3.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Apotex Inc 2011. DILT-CD (diltiazem hydrochloride extended-release capsules, USP). Toronto, Ontario, Canada:Apotex Inc. Available:
<a href="http://www.apotex.com/us/en/products/downloads/pil/dilt_ercp_ins.pdf">http://www.apotex.com/us/en/products/dow<span style="font-family:"Cambria Math","serif""></span>nloads/pil/dilt_ercp_ins.pdf
</a>[accessed 11 March 2011] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r4" id="r4"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">4.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Astra Aktiebolag, et al.
<i>v.</i> Andrx Pharmaceuticals Inc., et al</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"> 2002. Case no. 222 F.Supp. 423 (S.D.N.Y. 2002). U.S. District Court, Southern District of New York, 11 October.
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r5" id="r5"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">5.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Berna Biotech Ltd 2006. Vivotif (Typhoid Vaccine Live Oral Ty21a). Coral Gables, FL. Available:
<a href="http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142807.pdf">
http://www.fda.gov/downloads/BiologicsBl<span style="font-family:"Cambria Math","serif""></span>oodVaccines/Vaccines/ApprovedProducts/UC<span style="font-family:"Cambria Math","serif""></span>M142807.pdf
</a>[accessed 11 March 2011] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r6" id="r6"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">6.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">BTA Pharmaceuticals Inc 2010. Cardizem CD (Diltiazem Hydrochloride) Capsule. Available:
<a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=34903">http://dailymed.nlm.nih.gov/dailymed/dru<span style="font-family:"Cambria Math","serif""></span>gInfo.cfm?id=34903
</a>[accessed 11 March 2011] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r7" id="r7"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">7.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Canadian Pharmaceutical Association. 1995–2006</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">CPS:
Compendium of Pharmaceuticals and Specialties. Canadian Pharmaceutical Association. Ottowa, Ontario, Canada:
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r8" id="r8"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">8.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Corporacion Informasa 2010. Omesec—Omeprazole Capsule, Delayed Release. Available:
<a href="http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?id=18604&type=display">
http://dailymed.nlm.nih.gov/dailymed/fda<span style="font-family:"Cambria Math","serif""></span>/fdaDrugXsl.cfm?id=18604&type=display
</a>[accessed 11 March 2011] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r9" id="r9"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">9.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Crucell Switzerland LTD 2010. Vivotif: Thyphoid Vaccine Live Oral Attenuated TY21A. Available:
<a href="http://www.crucellvaccinescanada.com/pdf/100316_Product_Monograph_Vivotif_Canada_def_hc.pdf">
http://www.crucellvaccinescanada.com/pdf<span style="font-family:"Cambria Math","serif""></span>/100316_Product_Monograph_Vivotif_Canada<span style="font-family:"Cambria Math","serif""></span>_def_hc.pdf
</a>[accessed 19 January 2012] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r10" id="r10"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">10.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">DSHEA</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"> 1994.
Dietary Supplement Health and Education Act of 1994. Public Law 103–417. Available:
<a href="http://ods.od.nih.gov/about/dshea_wording.aspx">http://ods.od.nih.gov/about/dshea_wordin<span style="font-family:"Cambria Math","serif""></span>g.aspx
</a>[accessed 19 January 2012] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r11" id="r11"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">11.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">FDA (Food and Drug Administration) 2009. New Dietary Ingredients. Available:
<a href="http://www.gpo.gov/fdsys/pkg/USCODE-2010-title21/pdf/USCODE-2010-title21-chap9-subchapIV-sec350b.pdf">
http://www.gpo.gov/fdsys/pkg/USCODE-2010<span style="font-family:"Cambria Math","serif""></span>-title21/pdf/USCODE-2010-title21-chap9-s<span style="font-family:"Cambria Math","serif""></span>ubchapIV-sec350b.pdf
</a>[accessed 19 January 2012] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r12" id="r12"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">12.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">FDA (Food and Drug Administration) 2010a. FDA Drug Applications for Over-the-Counter Drugs. Available:
<a href="http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/over-the-counterdrugs/default.htm">
http://www.fda.gov/drugs/developmentappr<span style="font-family:"Cambria Math","serif""></span>ovalprocess/howdrugsaredevelopedandappro<span style="font-family:"Cambria Math","serif""></span>ved/approvalapplications/over-the-counte<span style="font-family:"Cambria Math","serif""></span>rdrugs/default.htm
</a>[accessed 11 March 2011] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r13" id="r13"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">13.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">FDA (Food and Drug Administration) 2010b. Inactive Ingredient Search for Approved Drug Products: Frequently Asked Questions. Available:
<a href="http://www.fda.gov/Drugs/InformationOnDrugs/ucm080123.htm">http://www.fda.gov/Drugs/InformationOnDr<span style="font-family:"Cambria Math","serif""></span>ugs/ucm080123.htm
</a>[accessed 11 March 2011] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r14" id="r14"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">14.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">FDA (Food and Drug Administration) 2011a. Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs;
General. Definitions. 21CFR210.3. Available: <a href="http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=210.3">
http://www.accessdata.fda.gov/scripts/cd<span style="font-family:"Cambria Math","serif""></span>rh/cfdocs/cfcfr/CFRSearch.cfm?fr=210.3
</a>[accessed 19 January 2012] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r15" id="r15"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">15.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">FDA (Food and Drug Administration) 2011b. Drugs@FDA: FDA Approved Drug Products. Available:
<a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/">http://www.accessdata.fda.gov/scripts/cd<span style="font-family:"Cambria Math","serif""></span>er/drugsatfda/
</a>[accessed 11 March 2011] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r16" id="r16"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">16.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Foster P..
</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">2005. Mode of action: impaired fetal Leydig cell function-effects on male reproductive development produced by certain phthalate esters. Crit Rev Toxicol
35(8-9):713–719. <a href="http://ehp03.niehs.nih.gov/article/findArticle.action?author=Foster&title=Mode%20of%20action:%20impaired%20fetal%20Leydig%20cell%20function-effects%20on%20male%20reproductive%20development%20produced%20by%20certain%20phthalate%20esters.&source=Crit%20Rev%20Toxicol&year=2005&firstpage=713&doi=">
<b><span style="font-size:7.0pt;text-transform:uppercase">Find this article online
</span></b></a><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r17" id="r17"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">17.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Hauser R, Duty S, Godfrey-Bailey L, Calafat AM.
</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">2004. Medications as a source of human exposure to phthalates. Environ Health Perspect 112:751–753.
<a href="http://ehp03.niehs.nih.gov/article/findArticle.action?author=Hauser&title=Medications%20as%20a%20source%20of%20human%20exposure%20to%20phthalates.&source=Environ%20Health%20Perspect&year=2004&firstpage=751&doi=">
<b><span style="font-size:7.0pt;text-transform:uppercase">Find this article online
</span></b></a><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r18" id="r18"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">18.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Health Canada 2011a. Drug Product Database. Available:
<a href="http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php">http://www.hc-sc.gc.ca/dhp-mps/prodpharm<span style="font-family:"Cambria Math","serif""></span>a/databasdon/index-eng.php
</a>[accessed 11 March 2011] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r19" id="r19"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">19.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Health Canada 2011b. Licensed Natural Health Products Database. Available:
<a href="http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/lnhpd-bdpsnh-eng.php">
http://www.hc-sc.gc.ca/dhp-mps/prodnatur<span style="font-family:"Cambria Math","serif""></span>/applications/licen-prod/lnhpd-bdpsnh-en<span style="font-family:"Cambria Math","serif""></span>g.php
</a>[accessed 11 March 2011] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r20" id="r20"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">20.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Hernández-Díaz S, Mitchell AA, Kelley KE, Calafat AM, Hauser R.
</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">2009. Medications as a potential source of exposure to phthalates in the U.S. population. Environ Health Perspect 117:185–189.
<a href="http://ehp03.niehs.nih.gov/article/findArticle.action?author=Hern%C3%A1ndez-D%C3%ADaz&title=Medications%20as%20a%20potential%20source%20of%20exposure%20to%20phthalates%20in%20the%20U.S.%20population.&source=Environ%20Health%20Perspect&year=2009&firstpage=185&doi=">
<b><span style="font-size:7.0pt;text-transform:uppercase">Find this article online
</span></b></a><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r21" id="r21"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">21.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Howdeshell K, Rider C, Wilson V, Gray LJ.
</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">2008. Mechanisms of action of phthalate esters, individually and in combination, to induce abnormal reproductive development in male laboratory rats. Environ
Res 108(2):168–179. <a href="http://ehp03.niehs.nih.gov/article/findArticle.action?author=Howdeshell&title=Mechanisms%20of%20action%20of%20phthalate%20esters,%20individually%20and%20in%20combination,%20to%20induce%20abnormal%20reproductive%20development%20in%20male%20laboratory%20rats.&source=Environ%20Res&year=2008&firstpage=168&doi=">
<b><span style="font-size:7.0pt;text-transform:uppercase">Find this article online
</span></b></a><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r22" id="r22"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">22.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Keller BO, Davidson AGF, Innis SM.
</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">2009. Phthalate metabolites in urine of CF patients are associated with use of enteric-coated pancreatic enzymes. Environ Toxicol Pharmacol 27(3):424–427.
<a href="http://ehp03.niehs.nih.gov/article/findArticle.action?author=Keller&title=Phthalate%20metabolites%20in%20urine%20of%20CF%20patients%20are%20associated%20with%20use%20of%20enteric-coated%20pancreatic%20enzymes.&source=Environ%20Toxicol%20Pharmacol&year=2009&firstpage=424&doi=">
<b><span style="font-size:7.0pt;text-transform:uppercase">Find this article online
</span></b></a><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r23" id="r23"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">23.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Mitchell JF 2011. Oral dosage forms that should not be crushed. Available:
<a href="http://www.ismp.org/tools/donotcrush.pdf">http://www.ismp.org/tools/donotcrush.pdf</a> [accessed 11 March 2011]
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r24" id="r24"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">24.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Mylan Pharmaceuticals Inc 2006. Diltiazem hydrochloride extended-release capsule. Canonsburg, PA:Mylan Pharmaceuticals Inc. Available:
<a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=44562">http://dailymed.nlm.nih.gov/dailymed/dru<span style="font-family:"Cambria Math","serif""></span>gInfo.cfm?id=44562
</a>[accessed 20 January 2012] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r25" id="r25"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">25.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Mylan Pharmaceuticals Inc 2010a. Verapamil Hydrochloride Capsule, Extended Release. Canonsburg, PA:Mylan Pharmaceuticals Inc. Available:
<a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=21863">http://dailymed.nlm.nih.gov/dailymed/dru<span style="font-family:"Cambria Math","serif""></span>gInfo.cfm?id=21863
</a>[accessed 11 March 2011] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r26" id="r26"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">26.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Mylan Pharmaceuticals Inc 2010b. Verapamil Hydrochloride Capsule, Extended Release (PM). Available:
<a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=33906">http://dailymed.nlm.nih.gov/dailymed/dru<span style="font-family:"Cambria Math","serif""></span>gInfo.cfm?id=33906
</a>[accessed 11 March 2011] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r27" id="r27"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">27.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">NLM (National Library of Medicine) 2011a. DailyMed. Available:
<a href="http://dailymed.nlm.nih.gov">http://dailymed.nlm.nih.gov</a> [accessed 11 March 2011]
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r28" id="r28"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">28.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">NLM (National Library of Medicine) 2011b. Dietary Supplements Labels Database. Available:
<a href="http://dietarysupplements.nlm.nih.gov">http://dietarysupplements.nlm.nih.gov</a> [accessed 11 March 2011]
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r29" id="r29"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">29.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Osterberg RE, See NA.
</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">2003. Toxicity of excipients—a food and drug administration perspective. Int J Toxicol 22(5):377–380.
<a href="http://ehp03.niehs.nih.gov/article/findArticle.action?author=Osterberg&title=Toxicity%20of%20excipients%E2%80%94a%20food%20and%20drug%20administration%20perspective.&source=Int%20J%20Toxicol&year=2003&firstpage=377&doi=">
<b><span style="font-size:7.0pt;text-transform:uppercase">Find this article online
</span></b></a><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r30" id="r30"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">30.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Reed Technology and Information Services Inc 2011. LabelDataPlus. Available:
<a href="http://www.labeldataplus.com/">http://www.labeldataplus.com/</a>[accessed 11 March 2011]
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r31" id="r31"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">31.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Rowe RC, Sheskey PJ, Quinn ME, eds</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">
2009. Handbook of Pharmaceutical Excipients. 6th ed. Washington, DC: American Pharmaceutical Association.
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r32" id="r32"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">32.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Shire LLC
<i>v</i>. Nostrum Pharmaceuticals Inc. et al</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"> 2008. Case No. 3: 08-cv-03309. District Court of New Jersey, 2 July.
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r33" id="r33"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">33.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Silva MJ, Barr DB, Reidy JA, Malek NA, Hodge CC, Caudill SP, et al.
</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">2004. Urinary levels of seven phthalate metabolites in the U.S. population from the National Health and Nutrition Examination Survey (NHANES) 1999–2000. Environ
Health Perspect 112:331–338. <a href="http://ehp03.niehs.nih.gov/article/findArticle.action?author=Silva&title=Urinary%20levels%20of%20seven%20phthalate%20metabolites%20in%20the%20U.S.%20population%20from%20the%20National%20Health%20and%20Nutrition%20Examination%20Survey%20(NHANES)%201999%E2%80%932000.&source=Environ%20Health%20Perspect&year=2004&firstpage=331&doi=">
<b><span style="font-size:7.0pt;text-transform:uppercase">Find this article online
</span></b></a><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r34" id="r34"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">34.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Solvay Pharmaceuticals Inc 2006. Creon Minimicrospheres. Marietta, GA:Solvay Pharmaceuticals Inc. Available:
<a href="http://www.creon-us.com/Content/assets/pdf/CREON%205,%2010,%2020%20Prescribing%20Information.pdf">
http://www.creon-us.com/Content/assets/p<span style="font-family:"Cambria Math","serif""></span>df/CREON%205,%2010,%2020%20Prescribing%2<span style="font-family:"Cambria Math","serif""></span>0Information.pdf
</a>[accessed 23 January 2012] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r35" id="r35"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">35.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Steinberg M, Silverstein I..
</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">2003. The use of unallowed excipients. Int J Toxicol 22(5):373–375.
<a href="http://ehp03.niehs.nih.gov/article/findArticle.action?author=Steinberg&title=The%20use%20of%20unallowed%20excipients.&source=Int%20J%20Toxicol&year=2003&firstpage=373&doi=">
<b><span style="font-size:7.0pt;text-transform:uppercase">Find this article online
</span></b></a><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r36" id="r36"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">36.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Swan SH.
</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">2008. Environmental phthalate exposure in relation to reproductive outcomes and other health endpoints in humans. Environ Res 108(2):177–184.
<a href="http://ehp03.niehs.nih.gov/article/findArticle.action?author=Swan&title=Environmental%20phthalate%20exposure%20in%20relation%20to%20reproductive%20outcomes%20and%20other%20health%20endpoints%20in%20humans.&source=Environ%20Res&year=2008&firstpage=177&doi=">
<b><span style="font-size:7.0pt;text-transform:uppercase">Find this article online
</span></b></a><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r37" id="r37"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">37.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Thomson Healthcare. 1995–2010a</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Physicians’
Desk Reference. Montvale, NJ: Thomson Healthcare. <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r38" id="r38"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">38.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Thomson Healthcare. 1995–2010b</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Physicians’
Desk Reference for Nonprescription Drugs, Dietary Supplements, and Herbs. Montvale, NJ: Thomson Healthcare.
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r39" id="r39"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">39.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Thomson PDR</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">
2006. Drugs that should not be crushed. In: 2006 Red Book: Pharmacy’s Fundamental Reference. 110th ed. Montvale, NJ: Thomson PDR, 40–44.
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r40" id="r40"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">40.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">U.S. Pharmacopeial Convention</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">
2009. Labeling of inactive ingredients. In: The United States Pharmacopeia—National Formulary. USP 32/NF 27. Rockville, MD: U.S. Pharmacopeial Convention, 599.
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r41" id="r41"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">41.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Warner Chilcott Pharmaceuticals Inc</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">
2010a. Asacol (Mesalamine) Delayed-Release Tablets. Mason, OH: Warner Chilcott Pharmaceuticals Inc.
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r42" id="r42"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">42.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span class="authors4"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Warner Chilcott Pharmaceuticals Inc</span></span><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">
2010b. Asacol HD (Mesalamine) Delayed-Release Tablets. Mason, OH: Warner Chilcott Pharmaceuticals Inc.
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r43" id="r43"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">43.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Watson Pharma Inc 2008. Diltia XT (Diltiazem Hydrochloride) Capsule, Extended Release. Available:
<a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8656">http://dailymed.nlm.nih.gov/dailymed/dru<span style="font-family:"Cambria Math","serif""></span>gInfo.cfm?id=8656
</a>[accessed 11 March 2011] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r44" id="r44"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">44.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Wockhardt USA LLC 2007. Ranitidine Tablet, Coated, 150 mg. Available:
<a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17165">http://dailymed.nlm.nih.gov/dailymed/dru<span style="font-family:"Cambria Math","serif""></span>gInfo.cfm?id=17165
</a>[accessed 11 March 2011] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r45" id="r45"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">45.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Wockhardt USA LLC 2008. Ranitidine Tablet, Coated, 75 mg. Available:
<a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17159">http://dailymed.nlm.nih.gov/dailymed/dru<span style="font-family:"Cambria Math","serif""></span>gInfo.cfm?id=17159
</a>[accessed 11 March 2011] <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:22.5pt;text-indent:-.25in;line-height:21.6pt;mso-list:l0 level1 lfo1">
<a name="r46" id="r46"></a><![if !supportLists]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030"><span style="mso-list:Ignore">46.<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030">Wockhardt USA LLC 2009. Ranitidine (Ranitidine Hydrochloride) Tablet. Parsippany, NJ:Wockhardt USA LLC. Available:
<a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=15325">http://dailymed.nlm.nih.gov/dailymed/dru<span style="font-family:"Cambria Math","serif""></span>gInfo.cfm?id=15325
</a>[accessed 11 March 2011] <o:p></o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;margin-left:.5in;line-height:16.8pt">
<span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030;display:none"> <o:p></o:p></span></p>
<p class="MsoNormal" style="line-height:16.8pt"><span lang="EN" style="font-size:8.0pt;font-family:"Verdana","sans-serif";color:#303030;display:none"> <o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:"Times New Roman","serif";color:#000099"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:"Times New Roman","serif";color:#000099"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:"Times New Roman","serif";color:#000099"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:10.0pt;font-family:"Times New Roman","serif";color:navy">Deborah L. DeBiasi</span><span style="font-family:"Times New Roman","serif";color:navy"><br>
</span><b><span style="font-size:10.0pt;font-family:"Times New Roman","serif";color:navy">Email: Deborah.DeBiasi@deq.virginia.gov</span></b><b><i><span style="font-size:10.0pt;font-family:"Times New Roman","serif";color:red"><br>
</span></i></b><span style="font-size:10.0pt;font-family:"Times New Roman","serif";color:navy">WEB site address:
<a href="http://www.deq.virginia.gov/">www.deq.virginia.gov</a></span><span style="font-family:"Times New Roman","serif";color:navy"><br>
</span><span style="font-size:10.0pt;font-family:"Times New Roman","serif";color:navy">Virginia Department of Environmental Quality</span><span style="font-family:"Times New Roman","serif";color:navy"><br>
</span><span style="font-size:10.0pt;font-family:"Times New Roman","serif";color:navy">Office of Water Permit and Compliance Assistance Programs</span><span style="font-family:"Times New Roman","serif";color:navy"><br>
</span><span style="font-size:10.0pt;font-family:"Times New Roman","serif";color:navy">Industrial Pretreatment/Whole Effluent Toxicity (WET) Program</span><span style="font-family:"Times New Roman","serif";color:navy"><br>
</span><span style="font-size:10.0pt;font-family:"Times New Roman","serif";color:navy">PPCPs, EDCs, and Microconstituents</span><span style="font-family:"Times New Roman","serif";color:navy">
<a href="http://www.deq.virginia.gov/Programs/Water/PermittingCompliance/PollutionDischargeElimination/Microconstituents.aspx">
http://www.deq.virginia.gov/Programs/Water/PermittingCompliance/PollutionDischargeElimination/Microconstituents.aspx</a></span><span style="font-size:10.0pt;font-family:"Times New Roman","serif";color:navy"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:10.0pt;font-family:"Times New Roman","serif";color:navy">Mail: P.O. Box 1105, Richmond, VA 23218</span><span style="font-family:"Times New Roman","serif";color:navy"><br>
</span><span style="font-size:10.0pt;font-family:"Times New Roman","serif";color:navy">Location: 629 E. Main Street, Richmond, VA 23219</span><span style="font-family:"Times New Roman","serif";color:navy"><br>
</span><span style="font-size:10.0pt;font-family:"Times New Roman","serif";color:navy">PH: 804-698-4028 FAX: 804-698-4032<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:10.0pt;font-family:"Times New Roman","serif";color:red">5th DEA sponsored Drug Take Back Sept 29, 2012 10-2</span><span style="font-size:10.0pt;font-family:"Times New Roman","serif";color:navy">
<a href="www.dea.gov">www.dea.gov</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:10.0pt;font-family:"Times New Roman","serif";color:#000099"><o:p> </o:p></span></p>
<p class="MsoNormal"><o:p> </o:p></p>
</div>
</body>
</html>